BioSpace News Archive

Centers for Medicare and Medicaid Services announced that it updated its lung cancer screening eligibility guidelines for people covered by Medicare to be similar to the U.S.

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced the pricing of an upsized, underwritten public offering of 4,545,454 shares of its common stock at a price to the public of $55.00 per share.

The U.S. Food and Drug Administration (FDA) held a public Oncology Drug Advisory Committee (ODAC) for sintilimab, which is under review for the first-line treatment of people with non-squamous non-small cell lung cancer (nsqNSCLC) based on the ORIENT-11 trial conducted exclusively in China.

TC Biopharm PLC announced the pricing of its initial public offering of 4,117,648 American Depositary Shares and warrants to purchase up to 8,235,296 ADSs, for aggregate gross proceeds of approximately $17.5 million, prior to deducting underwriting discounts, commissions, and other offering expenses.

Surgalign Holdings, Inc. announced the pricing of its previously announced underwritten public offering of 43,478,264 shares of its common stock and warrants to purchase up to an aggregate of 32,608,698 shares of common stock at a combined effective public offering price of $0.46 per share of common stock and accompanying 0.75 of a warrant.